CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 229 enrolled
Drug / intervention
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mgdrug
Likely dose
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04318210
NCT04318210N/ACompleted
CompareCT.gov

Open Label Extension (OLE) of the Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana

Centers for Disease Control and Prevention·interventional·Posted Mar 23, 2020·Updated May 13, 2022

In Brief

A clinical study evaluating Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg for HIV Infections. Completed, enrolled 229 participants.

Detailed Summary

This study is an open label and is an extension to the TDF2 study in which the investigators offered daily oral tenofovir/emtricitabine (TDF/FTC) for a maximum of 12 months to HIV uninfected former participants of the TDF2 study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
Countries--
CollaboratorsBotswana Ministry of Health

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 23, 2020
Enrollment StartOct 1, 2012
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.3 years ago

Interventions

Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mgdrug